Synonyms: MMPD | VX-497 | VX497
Compound class:
Synthetic organic
Comment: Merimepodib is an orally bioavailable, non-competitive inhibitor of inosine monophosphate dehydrogenase (IMPDH) [4]. It has antiviral activity, suppressing replication of Zika virus (ZIKV) [2], hepatitis C virus (HCV), and other emerging viral pathogens [5]. IMPDH inhibition reduces intracellular guanine nucleotide levels, thus limiting RNA and DNA synthesis both for cellular proliferation, and for viral replication inside host cells. Experimental evidence shows that the activity of merimepodib can augment the anti-replicative effects of other antivirals such as ribavirin and T-705 (favipiravir).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Dhar TG, Shen Z, Guo J, Liu C, Watterson SH, Gu HH, Pitts WJ, Fleener CA, Rouleau KA, Sherbina NZ et al.. (2002)
Discovery of N-[2-[2-[[3-methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a novel and potent inhibitor of inosine monophosphate dehydrogenase with excellent in vivo activity. J Med Chem, 45 (11): 2127-30. [PMID:12014950] |
2. Kamiyama N, Soma R, Hidano S, Watanabe K, Umekita H, Fukuda C, Noguchi K, Gendo Y, Ozaki T, Sonoda A et al.. (2017)
Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice. Antiviral Res, 146: 1-11. [PMID:28818572] |
3. Marcellin P, Horsmans Y, Nevens F, Grange JD, Bronowicki JP, Vetter D, Purdy S, Garg V, Bengtsson L, McNair L et al.. (2007)
Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C. J Hepatol, 47 (4): 476-83. [PMID:17629590] |
4. Sintchak MD, Nimmesgern E. (2000)
The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology, 47 (2-3): 163-84. [PMID:10878288] |
5. Tong X, Smith J, Bukreyeva N, Koma T, Manning JT, Kalkeri R, Kwong AD, Paessler S. (2018)
Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens. Antiviral Res, 149: 34-40. [PMID:29126899] |